Characterizing Benzo[]pyrene-induced  mutation spectrum in transgenic mice using next-generation sequencing by unknown
RESEARCH ARTICLE Open Access
Characterizing Benzo[a]pyrene-induced
lacZ mutation spectrum in transgenic mice
using next-generation sequencing
Marc A. Beal1,2, Rémi Gagné2, Andrew Williams2, Francesco Marchetti2 and Carole L. Yauk2*
Abstract
Background: The transgenic rodent mutation reporter assay provides an efficient approach to identify mutagenic
agents in vivo. A major advantage of this assay is that mutant reporter transgenes can be sequenced to provide
information on the mode of action of a mutagen and to identify clonally expanded mutations. However,
conventional DNA sequence analysis is laborious and expensive for long transgenes, such as lacZ (3096 bp), and is
not normally implemented in routine screening.
Methods: We developed a high-throughput next-generation sequencing (NGS) approach to simultaneously sequence
large numbers of barcoded mutant lacZ transgenes from different animals. We collected 3872 mutants derived from
the bone marrow DNA of six Muta™Mouse males exposed to the well-established mutagen benzo[a]pyrene (BaP) and
six solvent-exposed controls. Mutants within animal samples were pooled, barcoded, and then sequenced using NGS.
Results: We identified 1652 mutant sequences from 1006 independent mutations that underwent clonal expansion.
This deep sequencing analysis of mutation spectrum demonstrated that BaP causes primarily guanine transversions
(e.g. G:C→ T:A), which is highly consistent with previous studies employing Sanger sequencing. Furthermore, we
identified novel mutational hotspots in the lacZ transgene that were previously uncharacterized by Sanger sequencing.
Deep sequencing also allowed for an unprecedented ability to correct for clonal expansion events, improving the
sensitivity of the mutation reporter assay by 50 %.
Conclusion: These results demonstrate that the high-throughput nature and reduced costs offered by NGS provide a
sensitive and fast approach for elucidating and comparing mutagenic mechanisms of various agents among tissues
and enabling improved evaluation of genotoxins.
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Background
Transgenic mutation reporter rodent models, such as
Muta™Mouse [1], enable the detection of spontaneous and
induced mutations in vivo (reviewed in ref. [2]) and the
identification of chemical mutagens. These transgenic ro-
dents carry neutral reporter transgenes that can be easily
recovered and detected in a bacterial host when mutated.
Studies using the transgenic rodent (TGR) mutation re-
porter assay are very efficient and commonly used. The
Organisation for Economic Co-operation and Develop-
ment (OECD) has recently established guidelines for
mutagenicity testing using this assay [3]. One major ad-
vantage of the TGR assay is that mutant transgenes can be
sequenced to provide mechanistic insight into spontan-
eous and induced mutagenesis. DNA sequence analysis of
mutations offers several major benefits in genetic toxicol-
ogy: 1) mutation spectrum identifies the target nucleotides
and types of mutations providing information on the mu-
tagen’s mode of action; 2) it can be used to correct for
clonal expansion of mutant transgenes for a more accur-
ate calculation of mutation frequency (versus mutant
frequency); 3) it allows for a full characterization of muta-
tional hotspots across a specific locus; 4) it permits a com-
parison of mechanisms of mutagenesis operating in
different target tissues; and 5) differences in mutation
spectra between treated and control groups can further
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support a mutagenic effect, especially for weak mutagens.
Thus, sequence analysis provides the TGR assay with a
depth of information that is not available in most geno-
toxicity assays.
One of the most commonly used reporter transgenes
is the bacterial lacZ gene because there is a simple, effi-
cient, and robust positive selection method for identify-
ing lacZ mutations in Escherichia coli (E. coli) [4].
Mutant detection is conducted by extracting DNA from
the tissues of exposed lacZ-carrying transgenic rodents,
packaging of the lacZ transgene into bacteriophage and
infecting host E. coli. Under selective conditions, only
phage particles with mutated lacZ genes will be able to
form plaques. Mutant frequency is calculated as the pro-
portion of mutant plaques versus total plaques under
non-selective conditions. The lacZ coding sequence is the
longest of the mutation reporter transgenes (3096 bp) and
thus has many target nucleotide positions where muta-
tions can induce the mutant phenotype, making it a very
sensitive reporter. However, the length of the lacZ gene
poses challenges for sequence analysis of mutants. For this
reason, few studies have sequenced the lacZ transgene to
characterize mutation spectra following mutagen chal-
lenge [4–10]. Sequencing lacZ requires a complementa-
tion assay to narrow down the mutation location, followed
by several Sanger sequencing reactions of the section con-
taining the mutant [5, 6, 9, 10]. Therefore, the number of
mutants that can be sequenced in an experiment is limited
and most studies generally only sequence a few hundred
mutants in total across their experimental groups. The
majority of studies conducting mutation spectrum analysis
use different and much shorter mutation reporter genes
(cII, 294 bp; gpt, 456 bp; lacI, 1080 bp) because they are
small enough to be sequenced using Sanger sequencing.
Next-generation sequencing (NGS) had been used to
target and sequence pools of cII mutants from Big Blue®
mice [11]. These authors pooled 150 cII mutants per
sample and then sequenced 1776 mutations using 454
pyrosequencing to characterize the mutation spectra of
ultraviolet radiation, 4-aminobiphenyl, and second-hand
smoke, demonstrating the power of using NGS to se-
quence reporter genes. However, the short cII transgene
is not as sensitive to induced mutations as longer genes
and is therefore used much less frequently for routine
screening (only ~2 % of studies using Big Blue® or
Muta™Mouse actually measure mutations in the cII gene
[2]). With the advent of NGS, targeted sequencing of
large fragments is now possible [12], and with the high-
throughput nature of this technology, thousands of long
fragments, such as the lacZ gene, can be sequenced in a
single run. Thus, NGS can be adapted to identify muta-
tions within longer reporter genes enabling the routine
incorporation of mutation spectrum analysis into the
standard TGR assay.
Here we developed a high-throughput and cost-effective
approach that uses NGS to characterize lacZ mutation
spectra in the Muta™Mouse model. We collected lacZ
mutants from the bone marrow of control and benzo[a]-
pyrene (BaP) treated mice. BaP is a model mutagen
known to form bulky DNA adducts with guanine bases,
inducing primarily G:C → T:A transversions [6, 13–17].
Barcoding these individual mutant plaques would allow
for the sequence from each plaque to be followed inde-
pendently. However, this approach would not be any more
efficient or cost-effective than Sanger sequencing individ-
ual mutants (Sanger: PCR amplification of multiple ampli-
cons for sequencing vs. NGS: building a library). In the
present work, we pooled mutants from each animal in a
mixture, barcoded the mixture, and sequenced all the
mutants in that mixture at the same time under the same
barcode using an Ion Proton™ sequencer. This approach is
much more efficient but does not allow us to track the
mutations within a single plaque. Rather than assigning
mutants to a specific plaque, mutations are identified
within the pool and considered together as representative
of the mouse sample. Using this approach, we enriched
and sequenced an unprecedented 3872 lacZ mutant pla-
ques from control and BaP-exposed samples in a single
sequencing run and established the BaP-induced mutation
spectrum with unparalleled precision. We developed an
analytical pipeline to reduce false positive mutants (PCR
and sequencing artefacts) that includes the use of tech-
nical replicates and stringent filtering approaches. We
applied our pipeline to determine the degree of clonal
expansions and make adjustments to determine mutation
frequency within our population of mutants for each
mouse, to precisely characterize spontaneous and BaP-
induced mutation spectrum, and to determine the muta-




Six Muta™Mouse males (approximately 15 weeks of age;
strain 40.6 carrying 29.0 ± 4.0 copies of lacZ on chromo-
some 3 [18]) were exposed daily to BaP dissolved in
olive oil by oral gavage for 28 days (100 mg/kg body
weight/day). An additional six males received olive oil
and served as the vehicle controls. Three days after the
last treatment, mice were anaesthetized with isofluorane
and euthanized via cervical dislocation. Bone marrow
was isolated from the mice by flushing the femurs with
1X phosphate-buffered saline. After brief centrifugation
and supernatant removal, the pellet was flash-frozen in
liquid nitrogen and then stored at −80 °C. All animal
procedures were carried out under conditions approved
by the Health Canada Ottawa Animal Care Committee.
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Muta™Mouse lacZ mutation analysis
Bone marrow was thawed, digested in 5 mL of lysis buf-
fer (10 mM Tris–HCl, pH 7.6, 10 mM ethylenediamine-
tetraacetic acid (EDTA), 100 mM NaCl, 1 % sodium
dodecyl sulfate (w/v), 1 mg/mL Proteinase K), and incu-
bated at 37 °C overnight with gentle shaking. Genomic
DNA was then isolated using a phenol/chloroform ex-
traction procedure described previously [4, 5]. DNA was
dissolved in 100 μL of TE buffer (10 mM Tris pH 7.6,
1 mM EDTA) and stored at 4 °C for several days before
use. LacZ transgene mutants present in the genomic
DNA were identified using the Phenyl-β-D-galactopyra-
noside (P-gal) positive selection assay [4]. Briefly, the
λgt10lacZ construct was packaged into phage particles
through the cohesive ends (cos sites) using the Trans-
pack™ lambda packaging system (Agilent, Santa Clara,
CA). Packaged phage particles were subsequently mixed
with the host bacterium (E. coli lacZ−, galE−, recA−,
pAA119 with galT and galK) [19] in order to infect the
E. coli with the lacZ construct. The E. coli were then
plated on minimal medium containing 0.3 % (w/v) P-gal
and incubated overnight at 37 °C. P-gal is toxic to galE−
strains that express a functional copy of lacZ, and thus,
only E. coli receiving a mutated copy of the lacZ tran-
script will form plaques on the P-Gal medium. Packaged
phage particles were concurrently plated on titre plates
without P-Gal to determine the total plaque-forming
units (pfu). The lacZ mutant frequencies were then cal-
culated by determining the ratio of mutant pfu to total
pfu. The experimental design and lacZ mutation analysis
used in this study followed OECD guidelines [3]. For
more information on the lacZ mutation assay, there is a
recently published video describing the assay and pro-
cedural steps used here [20].
lacZ mutant plaque collection and preparation for
next-generation sequencing
The procedure used by Besaratinia et al. [11] to amplify
cII mutant plaques was adapted here for lacZ mutant
plaques. Figure 1 shows a brief overview of the workflow
used in this experiment. After the lacZ positive selection
assay was performed, lacZ mutant plaques from the
bone marrow of each animal were collected using a
transfer pipet and pooled together into microtubes con-
taining autoclaved milliQ sterile water (0.3 mutants/μL;
1 sample per tube). All of the mutants from a single ani-
mal were pooled together in a single microtube. Thus,
mutations were not assigned to individual plaques; ra-
ther, all mutations within an individual mouse were
identified by alignment of each read against the lacZ
gene. For a negative control, wild-type plaques with no
expected mutations were collected and processed for se-
quencing. Microtubes containing pooled plaques were
boiled for 5 min and then centrifuged at 18,000 g for
5 min. The supernatant was immediately transferred to a
new microtube for storage, and 10 μL of the supernatant
was transferred to another microtube for PCR. To con-
trol for the introduction of PCR errors, each pool of mu-
tants was amplified in two separate reactions (i.e., two
technical replicates per DNA pool). As the two replicates
contain the same mutant DNA, it is expected that the
same mutation should be present in both technical repli-
cate sequences. The 30 μL PCR mastermix contained a
final concentration of 1X PCR buffer, 1X Q solution, 200
nM of each primer, 50 μM dNTP, and 2.5 Units Taq DNA
polymerase (Qiagen, Valencia, CA). The PCR primers
used for amplification were custom designed using flank-
ing DNA outside of the lacZ gene [GenBank:J01636.1].
The forward and reverse primers were GGCTTTACAC
TTTATGCTTC and ACATAATGGATTTCCTTACG, re-
spectively. Amplification of the lacZ gene was carried out
using the following thermocycle program: 95 °C for 3 min;
30 cycles of 95 °C for 45 s, 50 °C for 1 min, 72 °C for
4 min; final extension at 72 °C for 7 min. PCR products
were purified using the QIAquick PCR purification kit
(Qiagen) prior to library preparation.
Ion Proton™ sequencing
Next-generation sequencing of the lacZ mutant products
was done in-house using an Ion Proton™ sequencer (Life
Technologies, Carlsbad, CA). The Ion Xpress™ Plus Li-
brary Kits and AB Library Builder™ (Ion Xpress Plus Li-
brary Protocol v. 1.00) were used to prepare one library
for each animal’s pool of mutants from purified PCR
Fig. 1 Brief overview of workflow used in this study
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products (for a total of 24 libraries). The procedure out-
lined in the user’s manual was followed with the excep-
tion of a 10 min custom shearing time and the
replacement of Agencourt® AMPure® XP Reagent with
SPRIselect® Reagent (Beckman Coulter, Brea, CA). The
P1 Adapter and barcoded A adapters provided in the
Ion Xpress™ Barcode Adapter kits were ligated to the
ends of the fragmented libraries (i.e., each PCR product
received a unique barcode). Gel electrophoresis of the
libraries was performed on E-Gel® SizeSelect™ 2 %
Agarose Gel using the E-Gel® iBase™ and visualized using
the E-Gel® Safe Imager™ transilluminator. Fragments that
were between ~175 and ~225 bp were excised from the
gel and purified using the Invitrogen™ PureLink® Quick
Gel Extraction Kit. Libraries were then amplified using
the Library Amplification Primer Mix (Ion Plus Frag-
ment Library Adapters kit) and Platinum® PCR Super-
Mix High Fidelity. Each amplified library was quantified/
qualified using the Agilent® High Sensitivity DNA Kit
and Agilent® Bioanalyzer® 2100 Instrument. Aliquots of
each library were pooled together for a total final concen-
tration of 16 pM. Emulsion PCR (em-PCR) of the pooled
libraries was carried out using Ion Sphere™ particles on
the Ion OneTouch™ 2 system. The Ion OneTouch™ ES was
used to enrich for particles containing em-PCR products
and the Qubit® 2.0 Fluorometer was used to assess the
quality of enrichment. Enriched particles were deposited
into the wells of an Ion P1™ chip (version 1) and se-
quenced by semi-conductor sequencing [21].
Bioinformatics
The Proton™ Torrent Server version 3.6.2 interpreted
the sequencing data and generated FASTQ files for each
barcoded library. Reads were trimmed to remove low
quality base calls and aligned to the reference se-
quence [GenBank: J01636.1] using Bowtie2 [22] (Settings:
“– local” mode with “– very-sensitive-local”). The
lacZ gene in our Muta™Mouse colony has four varia-
tions [6] relative to the reference coding sequence
[GenBank:V00296.1] [23] that were corrected for.
Following alignment, a pileup format was prepared for
each sample using SAMtools [24]. From the sample
pileups, the number of reads that were wild-type or
polymorphic (base substitutions/indels) was determined
for each nucleotide position of the lacZ gene. At each
nucleotide position, a proportion of reads is expected to
carry a technical artefact (e.g., PCR artefacts and sequen-
cing noise) for each possible mutation type (referred to
as the false mutation proportion: see glossary in Table 1).
However, these false mutation calls are consistent across
samples (Additional file 1: Figure S1) and thus the false
mutation proportion of each mutation type can be esti-
mated individually at each nucleotide position. In order to
prevent outlier libraries from influencing the background
reading, false mutation proportions were estimated by cal-
culating the median rate of occurrence of each mutation
type across all samples for each nucleotide position. The
data were then normalized by subtracting the false muta-
tion proportion from the total mutation proportion to
determine the true mutation proportion at each nucleo-
tide position (Additional file 1: Figure S2; see glossary for
clarification). Due to homopolymer sequencing errors, the
false mutation proportion for some insertions/deletions
(indels) can be much higher than false mutation propor-
tions for base substitutions. To minimize false indel calls,
indels appearing with a false mutation proportion higher
than the highest false mutation proportion for base substi-
tution calls were ignored.
Variants that remained following the false mutation
proportion subtraction were considered mutations if the
true mutation proportion was above threshold values
determined based on the number of mutant plaques re-
covered from each sample and used in the sequencing
(Additional file 1: Table S1). For example, if a mutant
pool for an individual animal consisted of 100 plaques, a
single mutation should be present in approximately 1 %
of the sequenced reads (1 % of reads would have the
variant while 99 % would have the reference nucleotide).
Table 1 Glossary
Mutant – A plaque, grown on P-Gal media, that contains a loss of
function mutation in the lacZ transgene.
Mutation – The change in DNA sequence (point mutation, indel)
that knocks out the function of the lacZ transgene. There may also
be silent mutations that can co-occur on the same lacZ copy as a
loss of function mutation (“hitchhiker mutations”).
Clonal Expansion – When a cell containing a mutation produces
daughter cells containing that same mutation, propagating it
throughout the tissue.
False Mutation Proportion – At each nucleotide position, a
proportion of the reads may contain a technical artefact and
this proportion is consistent across samples. For example, if at
position 25, the median frequency of G→ A substitutions across
all samples was one in every thousand reads, the false mutation
proportion would be 0.001.
Total Mutation Proportion – At each nucleotide position, this is the
mutation proportion for each mutation type within a single sample.
For example, if sample 3 had a G → A substitutions at position 25 in
0.5 % of reads, the total mutation proportion would be 0.005.
True Mutation Proportion – The true mutation proportion of each
mutation type at each position is determined by subtracting the false
mutation proportion from the total mutation proportion. In the above
example the true mutation proportion would be 0.004. This value is
used to determine mutation counts.
Independent Mutations – Mutations that appear multiple times in a
same sample due to clonal expansion are only counted as one
mutation per sample. For example, if sample 1 had five G→ A
substitutions at position 25, this would be called a single
independent mutation at position 25.
Recurrent Mutations – If a mutation occurs more than once
within a sample it is considered recurrent as is likely the result
of clonal expansion. In the previous example there are five G→ A
recurrent mutations at position 25.
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To determine the threshold that should be set for identi-
fying true mutations, the data were first analyzed using
three different thresholds to optimize the sensitivity of
the assay. The thresholds were set at: 1) the exact pro-
portion for the mutation expected; 2) 75 % of the
expected proportion; and 3) 50 % of the expected pro-
portion. Using the previous example, the thresholds
would be 0.01, 0.0075, and 0.005, respectively. In
addition, in order for a mutation to be counted it needed
to be present at values above the threshold in both tech-
nical replicates.
The average between the true mutation proportions of
each technical replicate was used to provide a rough es-
timation of the total number of each type of mutation.
For example, a base substitution present at a frequency
of 0.10 would be counted as ten mutations in a sample
that had a minimum threshold of 0.01. These values
were used to determine the distribution of mutations
across the lacZ gene for both the BaP-treated and con-
trol groups and identify mutation hotspots. In contrast,
only independent mutations were used to determine the
lacZ mutation spectra for both groups.
Finally, we examined the sequence sites of each spe-
cific mutation identified in the lacZ gene. The DNA
codon table was used to determine whether base substi-
tution changes observed in the coding sequence would
result in amino acid changes in the protein. Based on
this analysis, mutations were classified as nonsense, mis-
sense or silent.
Statistical analysis
Statistical analyses were performed using R program-
ming language to compare mutant frequencies and mu-
tation spectra between control and treated animals [25].
The lacZ mutant frequencies in the bone marrow of
control and BaP-treated animals were compared by Pois-
son Regression. Statistical comparisons of mutation
types between control and treated groups were done
using Pearson’s chi-squared test of independence.
Mutations that occurred more than once in the same
animal were considered to be derived from clonal expan-
sion (see glossary) from a single ‘independent’ event.
The formula of [(total mutations – independent muta-
tions)/total mutations] was used to estimate clonality.
To test the method’s ability to estimate clonality, eight
mutant plaques from different animals (each mutation
identified by Sanger sequencing) were subcloned and
then mixed together in different proportions (Additional
file 1: Table S2). One of these mixtures contained differ-
ent sized plaques to see whether plaque size affected
clonality estimation. As an additional control, 100 ran-
dom mutants from 100 different animals were pooled
together to estimate the ability to identify unique muta-
tions that were not expected to be clonally amplified.
The observed proportions recovered by sequencing were
then compared with the expected proportions of each
mutant mixture. A Fitting Linear Models algorithm
[26, 27] in R was used to estimate the limit of detec-
tion (LOD) for accurately quantifying mutant count
using NGS. The algorithm searches for the LOD with
the lowest squared error using 1000 iterations with de-
creasing step size. The model estimated that the LOD was
four mutants (horizontal blue line in Fig. 2) and thus
mutants with an observed count of four or less were set to
a count of one. Above the LOD, the relationship between
expected and observed mutant count is linear (P =
0.4249). Thus, using the LOD/Linear model we adjusted
the count of each mutant in the BaP experiment for
clonality measurements with the formula: Adjusted
Mutant Count = (Observed Count – Intercept) / Slope for
mutant counts > 4 where the y intercept = 0.3123 and the
slope = 1.1363. Clonality was then calculated based on the
adjusted mutant counts. For example, a count of three
mutations was adjusted to one mutation and a count of 50
mutations was adjusted to 44 mutations.
Results
lacZ mutant frequency
As expected, bone marrow lacZ mutant frequencies
were significantly higher in BaP-treated mice (701.7 ±
49.3 × 10−5) than control mice (8.6 ± 2.0 × 10−5) (P <
0.0001). This increase in mutant frequency is consistent
with previous results [28]. However, the spontaneous
mutant frequency was higher than expected based on
historical controls (example: [28]), mostly due to ani-
mal Control20, which had a mutant frequency of
17.8 × 10−5. This animal was included in the study to
test the method’s ability to detect clonal expansion.
Sequencing output and read coverage
Sequencing of the pooled libraries using one Ion P1™
chip (version 1) gave 87,666,405 reads of 95 bp mean
length for a total of 8.3 Gb. The number of usable reads
was reduced to 66 % after removal of polyclonal Ion
Sphere™ particles (29 %) obtained from the pooled li-
brary. Thus, the average nucleotide coverage per library
was 9.1 ± 0.4 × 104. The starts and ends of the reads
across the gene appeared to be uniform (Additional file
1: Figure S3).
False mutation proportion subtraction and threshold
comparisons
An analysis of our data using conventional approaches
revealed that most existing algorithms or variant callers
were not equipped to detect rare mutations in pooled sam-
ples. Thus, we explored the use of a false mutation propor-
tion subtraction methodology that we developed in-house.
False mutation proportion refers to the sequencing artefacts
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that occur by chance at each nucleotide position. We use
the term ‘proportion’ here to differentiate the proportion of
reads carrying errors (background noise) from reads with
true mutations. The false mutation proportions (see gloss-
ary for specific definition) for base substitutions ranged
from 1.70 × 10−5 to 2.15 × 10−2 (median: 4.25 × 10−3), and
from 1.64 × 10−5 to 4.64 × 10−1 (median: 7.52 × 10−3) for
indels (Additional file 1: Figure S4). As the number of indel
technical errors increase, the ability to reliably call muta-
tions diminishes. Thus, indels were only called if the false
mutation proportion was less than 2.15 × 10−2. Indels
occurring at sites with a false mutation proportion greater
than this were not included in the analysis. In the final ana-
lysis, this resulted in the removal of 21 out of 65 insertions
(3/6 control, 18/59 BaP) and 99 out of 297 deletions (31/53
control, 68/244 BaP).
After correcting for the false mutation proportion, we
explored mutation calling using three different thresh-
olds for optimization (Additional file 1: Table S1). With
the stringent threshold (i.e., the exact proportion ex-
pected), 152 and 854 independent mutations were recov-
ered in both technical replicates for the control and BaP
groups respectively (Table 2). The total number of muta-
tions (unadjusted by LOD/Linear model) recovered out
of 872 and 3000 mutant plaques from control and BaP-
treated samples were 583 (67 %) and 2077 (69 %),
respectively. Applying the two less stringent thresholds
increased the number of mutations called from 2660 to
2912 and 3282, respectively; however, the discrepancies
between technical replicates greatly increased. Thus, all
downstream analyses were done on mutations called
using the most stringent threshold. As expected, apply-
ing the most stringent threshold resulted in no mutation
calls for the wild-type plaques.
Detection of clonal expansion
We created five control libraries (Additional file 1: Table
S2) in which the number of mutations was known in
order to determine the ability of our NGS approach to
accurately predict the number of copies of each muta-
tion. In addition, a library of 100 random mutants was
sequenced to determine our ability to detect unique mu-
tations. For each mutation detected, we divided the true
mutation proportion by the expected mutation propor-
tion for a single mutation (threshold) to estimate the
number of copies of that mutation in any given sample.
In the library of 100 random mutants there were 49
independent mutants detected with a total count of 102
recurrent mutations, which is a higher proportion of
recurrent mutations than was expected [5]. It is possible
that some of the recurrent mutations occurred at mutation
hotspots. For example, five independent mutants and 15
recurrent mutations were detected at four of five known
mutation hotspots [8]. However, it is more likely that some
mutants were not detected while the count of the detected
mutants was overestimated. When the expected mutant
y = 1.1363x + 0.3123
y = x





Fig. 2 Correlation between observed and expected mutant counts. The red line shows a 1:1 ratio and the black line shows the true relationship
between expected and observed mutant count. The plot shows that mutants with low counts cannot be accurately quantified. This results in a
non-linear relationship between expected and observed mutant count (P < 0.0001). Hence, a limit of detection/linear model was used to adjust
the total mutation counts of each independent mutation
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count was compared with the observed mutant count in
the five control libraries (Fig. 2), we found that the count
of each mutant was overestimated. Therefore, a limit of
detection/linear model was developed to adjust the recur-
rent mutation counts of each independent mutation.
Based on the model, the total mutation count for the
library containing 100 random plaques was estimated to
be 55 mutations. The mutant count estimation for the
experimental libraries was 1652 mutant sequences (411
control, 1241 BaP) from 1006 independent mutations. A
total of 917 mutants in the experimental libraries fell
below the LOD, indicating a relatively small proportion of
mutants underwent clonal expansion. The adjusted aver-
age clonality in the control and BaP samples was 43 and
31 % respectively (Additional file 1: Table S3), which is
comparable to what was measured at the cII locus in the
same mice (O’Brien, unpublished) and in other studies [2].
After adjusting for clonality, the lacZ mutation frequen-
cies were 4.0 ± 1.0 × 10−5 and 484.0 ± 34.9 × 10−5 for con-
trol and BaP mice, respectively. The clonality adjustment
revealed that the raw control mutant frequency was ele-
vated in part by the presence of one outlier animal with
extensive clonal expansion (86 %). After correcting for
clonal expansion, the mutation frequency of this animal
was in line with the mutation frequency of the rest of the
animals (within one standard deviation of the mean;
Additional file 1: Table S3). The model for adjusting
clonality showed that BaP induction was 121-fold higher
than control.
lacZ mutation spectra and distribution
The BaP mutation spectrum in bone marrow had signifi-
cant differences from the control spectrum (Fig. 3). The
proportions of transitions, transversions, and indels were
0.35, 0.49, and 0.16 in the control and 0.14, 0.61, and
0.25 in the BaP animals, respectively. The proportion of
G:C → T:A and G:C → C:G transversions was signifi-
cantly increased in BaP-treated animals relative to con-
trols (P < 0.05). In addition, the proportion of G:C →
A:T transitions was reduced (P < 0.0001) following BaP
treatment. These findings are consistent with the lacI
mutation spectrum in BaP-treated mouse liver [29]
(Additional file 1: Figure S5). There were no significant
differences in the proportion of the other mutation types
between control and BaP-treated groups. When compar-
ing the absolute frequencies of each mutation type, BaP
exposure increased all mutation types above control
except for A:T → G:C transitions (Additional file 1: Fig-
ure S6). To further test the accuracy of our NGS data,
we compared the control and BaP-induced bone marrow
lacZ mutation spectrum with published mutation spec-
tra for transgene reporters from control and BaP-treated
mice. The comparisons of control (Additional file 1:
Figure S7) and BaP-induced (Additional file 1: Figure
S8) spectra were consistent with the published data
using Sanger sequencing, demonstrating that our NGS
approach accurately identifies mutation spectra.
Plotting the locations of the independent (Fig. 4) and
recurrent (Additional file 1: Figure S9) base substitutions
along the lacZ transgene to identify mutation hotspots
demonstrated that the majority of induced and spontan-
eous mutations were at G:C base pairs (Additional file 1:
Table S4). Within the lacZ transgene there are 12 short
CpG sequences ≥ 5 nucleotides long. At these CpG sites
there were five control point mutations (1G:C → A:T,
3G:C → T:A, 1G:C → C:G) and 36 BaP point mutations
(1G:C → A:T, 24G:C → T:A, 11G:C → C:G). All nucleo-
tide positions that had more than two independent
mutations were at G:C sites in both control and BaP
groups. Previously identified mutation hotspots in the
lacZ gene using Sanger sequencing, based on ~500
mutations [5–10], were also hotspots in our dataset
(Additional file 1: Figure S10). In all previous studies,
there were 67 nucleotide positions with more than one
mutation, and 51 (76 %) of these positions had a muta-
tion in our dataset. We found mutations at all of the
nucleotide positions that had more than four mutations
across the previously published mutation hotspots. In
the NGS data, there were 29 hotspots with more than
four independent mutations across the different animals;
Table 2 Summary of all mutations called using three different thresholds
Independent Mutations Total Mutations aMutants Removed
Threshold bBase Subs. cIns dDels Base Subs. Ins Dels Base Subs. Ins Dels
Control Stringent 127 3 22 542 7 34 14 101 117
Medium 159 7 27 574 7 39 18 193 223
Low 190 12 36 605 16 48 55 426 420
BaP Stringent 637 41 176 1583 66 428 108 750 577
Medium 767 60 239 1714 85 493 183 1139 818
Low 921 125 338 1869 151 593 374 1846 1284
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of these nucleotide positions only two (7 %) were not
identified using Sanger sequencing in previous studies.
The majority of indels that we observed were gains/
losses of single nucleotides. There were 34 indels (of 242
in total) that involved two nucleotides: 32/198 deletions
(3/22 control, 29/176 BaP); and 2/44 insertions (0/3 con-
trol, 2/41 BaP). Detecting indels was not as reliable as
detecting base substitutions due to difficulty in sequen-
cing homopolymer regions; sequencing accuracy of ho-
mopolymers falls to 97 % at homopolymer stretches of
five or more base pairs [21]. In the lacZ gene, there are
591 short homopolymers (462 two mononucleotide re-
peats; 97 three mononucleotide repeats; and 32 ≥4
mononucleotide repeats). This means that 1353 bp
(44 %) of the lacZ gene are within a short homopolymer.
To test for a homopolymer bias, indels were plotted
across the lacZ gene (Fig. 5, Additional file 1: Figure
S11). The numbers of mutations occurring inside or ad-
jacent to homopolymer stretches ≥ 3 bp long were: 2 out
of 3 control insertions, 5 out 22 control deletions, 7 out
of 41 BaP insertions, and 33 out of 176 BaP deletions
(Fig. 3). Furthermore, only ten (31 %) of the 32 longest
homopolymers in the lacZ gene had mutations within or
adjacent to the homopolymers. Thus, the false mutation
proportion subtraction accounted for many sequencing
artefacts occurring around homopolymer regions.
Using the coding sequence of lacZ, we identified the
amino acid changes that would result from each muta-
tion. This analysis revealed that the proportion of mis-
sense, nonsense, and silent mutations was 39, 59, and
Fig. 3 Relative proportion of control and BaP-induced lacZ mutations in bone marrow. Only independent mutations were considered. Mutation
types with asterisks are significantly different between control and treated groups. The light-colored boxes within indels represent the fraction of
indels that was inside or next to homopolymer stretches≥ 3 bp long. The error bars represent the standard error between samples
Fig. 4 Distribution of unique base substitutions across the lacZ transgene for control and BaP samples. BaP base substitutions are on the positive
y-axis and control substitutions are on the negative y-axis
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2 % in the control, and 50, 44, and 7 % in the BaP group,
respectively. The silent mutations that were identified by
NGS are likely “hitchhiker” mutations that occurred in
the same plaque as a phenotype-inducing mutation.
Sanger sequencing of mutant plaques shows that the
proportion of plaques with more than one mutation
(synonymous or non-synonymous) can be as high as
11 %, and the proportion of plaques with mutations
separated by hundreds of nucleotides is around 3 % [6].
Also, the proportion of silent mutations observed here is
consistent with the proportion of silent mutations de-
tected using Sanger sequencing (<6 %) [5, 6, 8–10, 29].
The number of missense, nonsense, and silent mutations
that occurred more than once at a nucleotide position
was 10, 7, and 0 (20, 9, and 0 %) for the control, and 55,
62, and 4 (18, 22, and 8 %) for the BaP, respectively. Tak-
ing both groups into account there were 66, 81, and 4
positions where there was more than one missense, non-
sense, and silent mutation, respectively. The low number
of recurring silent mutations is as expected and rein-
forces the reliability of the data.
We also performed simulations, using random mutant
sampling, to determine the minimum number of mu-
tants per samples that would be sufficient to achieve a
consistent mutation spectrum in the BaP group. In this
simulation, mutations were sampled from 375, 348, 364,
360, and 299 BaP mutants (150, 142, 161, 138, and 139
BaP mutations) in five of the six treated animals, re-
spectively. One animal had to be excluded because some
of the mutation types did not occur frequently enough
for accurate simulations. There were no significant dif-
ferences in the mutation spectra of the five remaining
animals (P = 0.3). As shown in Additional file 1: Figure
S12, the results of our simulations demonstrated that
sequencing approximately 100 mutants from a mouse
provides an 80 % power to obtain the true mutation
spectrum for that individual (P < 0.05).
Discussion
We developed a simple, cost-effective, and high-throughput
method to characterize the mutation spectrum of a trans-
genic mutation reporter locus in rodents using targeted
NGS. This method can be adapted for any mutation
reporter model using any NGS platform. In addition, the
data analysis is simple and non-subjective. Using our con-
servative approach, we identified 1006 independent muta-
tions within the lacZ transgene allowing us to characterize
the spontaneous and BaP-induced mutation spectra with
unparalleled precision. As expected, BaP exposure induced
primarily G:C → T:A transversions. Our approach also
allowed us to identify 1652 total mutations (including
recurrent mutations that occurred more than once per
mouse), permitting clonal expansion correction and making
the assay 50 % more sensitive in detecting increases in
mutation frequencies. Furthermore, comparisons of our
NGS results with previous results obtained using Sanger
sequencing show that the mutation spectra (Fig. 3), muta-
tion hotspots (Additional file 1: Figure S10), and amino acid
changes were as expected, demonstrating the robustness of
our approach.
Characterization of the mutation spectra is important
for identifying which sites are targeted by chemicals to
elucidate mutagenic mechanism (e.g., what types of ad-
ducts are formed, faulty DNA repair processes, etc.). We
investigated the mutation signature of BaP because it is a
model carcinogen and its metabolic activation is well
understood [30, 31]. BaP is metabolized by cytochrome
P450 enzymes and epoxide hydrolase to mutagenic me-
tabolites including benzo[a]pyrene-7,8-dihydrodiol-9,10-
epoxide (BPDE) [31–33]. BPDE forms DNA adducts with
Fig. 5 Distribution of unique indels across the lacZ transgene for control and BaP samples. BaP indels are on the positive y-axis and control indels
are on the negative y-axis
Beal et al. BMC Genomics  (2015) 16:812 Page 9 of 13
the 2-amino group (N2) of guanine, and to a lesser extent
with N6 and N4 of adenine and cytosine, respectively
[32–34]. BPDE also produces reactive oxygen species
through the spontaneous rearrangement of the epoxides
or redox cycling, which also react with DNA leading to
oxidative DNA damage, such as 8-oxo-deoxyguanosine
[32]. These BaP damaging events explain the high propor-
tion of guanine base substitutions, specifically G → T and
G → C, seen here in bone marrow. In total, 89 % of BaP-
induced mutations occurred at G:C nucleotides and all of
the BaP-associated mutation hotspots were at G:C nucleo-
tides. However, the refined mutation spectra obtained
from sequencing thousands of mutants demonstrated that
absolute mutation frequencies of all mutation types were
elevated relative to the control with the exception of
A:T → G:C transitions. Thus, BaP is a potent muta-
gen capable of inducing transversions at any nucleo-
tide and transitions at G:C nucleotides.
One of the main reasons for sequencing mutants is to
account for clonal expansion [3]. This can cause a tissue
sample to have a higher mutant frequency than the rest of
the samples within a group and falsely over-represents
independent mutation events. To correct for clonal ex-
pansion, a subset of the mutant plaques from the tissue
sample is sequenced to identify recurrent mutations aris-
ing from one progenitor cell that may be inflating the mu-
tant frequency. Recurrent mutations are only counted as
one mutation and the mutant frequency is adjusted ac-
cordingly (to reflect the true mutation frequency). Plotting
the mutation distribution of all animals revealed potential
clonal expansion events. Using the LOD/Linear model the
corrected clonality estimates were 43 and 31 % in the con-
trol and exposed groups respectively. Correcting for
clonality revealed that the fold increase in mutation fre-
quency following BaP treatment was ~120-fold. This sug-
gests that although NGS may overestimate the clonality of
a tissue sample, the overestimation is consistent across
samples and therefore a relative clonality comparison
between groups can be achieved.
It should also be noted that the number of mutants se-
quenced can influence the clonal expansion estimation.
In this study we sequenced a large number of mutants
unmatched by any other study, and for this reason we
may be seeing higher levels of clonality. Simulations
show that had only 25 mutations been sequenced per
animal (more typical of past experiments using Sanger
sequencing [35]), the clonality would have remained at
43 % in the control group, but would have been reduced
to 9 % in treated samples. The differences in clonality
between actual and simulated measurements highlight
the need to use caution when comparing clonality re-
sults determined by sequencing large versus small num-
bers of mutants. The lower clonality observed in the
treated group can be explained by the presence of
thousands of BaP-induced mutations that are reducing
the chance of randomly sampling spontaneous muta-
tions that were clonally expanded during mouse
development.
The need to account for clonality was clearly demon-
strated by the presence of one outlier control animal
with a high mutant frequency in our study (Additional
file 1: Table S3). Because of this outlier, which had 86 %
clonality, our control group had a mean mutant fre-
quency that was higher than expected based on previous
studies [2]. However, after correcting for clonal expan-
sion there was less variability in mutation frequencies
within each group. Furthermore, the adjusted spontan-
eous mutation frequency was consistent with historical
values for bone marrow from our laboratory [28, 36].
Finally, correcting for clonal expansion demonstrated
that the mutation induction caused by BaP was underes-
timated by 50 % in the standard non-sequenced based
approach. Had a weaker mutagen been tested, the trans-
genic rodent assay may have given a false-negative result
without adjustment of clonal expansion. These examples
show the added value of sequencing to measure clonality
when interpreting the results of the TGR assay and dem-
onstrate that our method can be used to correct for
clonal expansion events at the lacZ locus to improve the
reliability of reporter gene data.
There are notable strengths in our approach. First, our
method uses a simple false mutation proportion subtrac-
tion to minimize sequencing artefacts and alignment
errors. It is known that different NGS platforms and
alignment tools have biases that can introduce false
positives [37–40]. For example, the accuracy of semi-
conductor sequencing decreases with increased homopol-
ymer length [21], as is seen with pyrosequencing [41, 42].
However, these biases are consistent between the samples
at each nucleotide position (Additional file 1: Figure S1)
and thus can be corrected (Additional file 1: Figure S2).
After applying the correction, we were able to identify in-
dependent mutations along the lacZ gene and approxi-
mate the number of times each mutation occurred.
Second, we used technical replicates (two PCR amplifica-
tions) for each sample as a strategy to minimize the num-
ber of false-positives. This was done to account for errors
that occurred during PCR as a result of Taq replication
errors or thermal DNA damage [43, 44]. Using technical
replicates does not reduce the throughput of the sequen-
cing, and only marginally increases the cost of the experi-
ment. Although this approach is very conservative and
reduces the number of mutations called (i.e., we identified
1652 mutants from 3872 plaques), it is currently needed
to eliminate false-positives, especially for indels, and
accurately call mutations (Table 2). Thus, we strongly
recommend that technical replicates be used with this
method to control for PCR-based errors, allowing for
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accurate characterization of mutation spectra. Given the
significant increases in the number of mutants that can be
sequenced relative to Sanger sequencing, our stringent cri-
teria for calling mutations does not reduce the power of
the approach; indeed, we have sequenced an unprece-
dented number of lacZ mutations within a single experi-
ment. This method was designed to be modular; therefore,
researchers can explore the use of other bioinformatics
and statistical tools that best fit their data. Before setting
up this protocol in a laboratory, it is recommended that
experiments be conducted using positive and negative
controls to optimize parameters as we have done here.
The number of mutants that should be pooled per bar-
code must be considered carefully in the experimental
design. As the number of mutants increase, the threshold
to call a mutation decreases and the chance of identifying
an artefact as a mutation increases. In addition, having too
many mutants pooled per barcode will decrease the detec-
tion sensitivity of the NGS method. Contrarily, having too
few mutants will not provide an accurate mutation
spectrum. In order to approximate the number of mutants
that should be pooled per barcode, we performed multiple
data simulations based on the available results. These sim-
ulations show that sampling around 100 mutants per ani-
mal is sufficient to achieve reliable mutation spectra with
a power of 80 %, and therefore, pooling approximately 170
mutants per barcode (assuming a mutant recovery of
~60 %) should be more than enough for any sequencing
application. If sequencing of more mutations per sample
is desired, additional DNA barcodes can be used. Another
consideration is that the short length of the reads hinders
the detection of large indels or complex mutations (mul-
tiple mutations occurring across the same DNA mol-
ecule). However, read lengths for the different platforms
continue to increase [45] and may eventually increase to a
point where complex mutations can be detected with a
standard library.
Our method was designed using DNA barcoding to
allow for cost- and time-effective analysis of lacZ muta-
tion spectra. We estimate that the cost to sequence 3872
mutants using Sanger sequencing would be 20-fold
higher than using NGS in reagent costs alone. Further-
more, this sequencing can be done in a week using
NGS, while it would take at least 25 times as long using
Sanger sequencing. If more mutants were sequenced,
whether they were from the same samples or different
experiments, the difference in cost and time would be
greater. As demonstrated, there is an added bonus of se-
quencing large numbers of mutants: 1) mutation spectra
can be characterized with high precision; 2) novel muta-
tional hotspots can be identified (important for under-
standing an agent’s mode of action); and 3) silent
mutations present on a mutated transgene, which are
normally undetected, can be characterized. Considering
that each barcoded library was sequenced with an average
coverage of 91,000x (182,000x coverage per sample), sev-
eral more samples could have been sequenced, making this
approach highly efficient and amenable to the simultan-
eous sequencing of mutant plaques from different tissues
and/or chemical agents. Furthermore, the cost and time to
do these experiments will decline further as the throughput
of NGS increases.
Conclusions
In summary, we developed a high-throughput method
for targeted-sequencing of long mutant reporter genes,
specifically the lacZ transgene. The mutation spectra
determined using the NGS analytical process are highly
concordant with results using Sanger sequencing, demon-
strating the accuracy of the methodology. After the animal
exposure and tissue sample collection is complete, a whole
experiment, from the beginning of the transgenic rodent
assay to the end of the data analysis, can be done in less
than 3 weeks using our newly established data analysis.
The benefit of this method is that it can sequence as many
mutants as the TGR assay can produce. Thus, this method
has the potential to sequence hundreds to thousands of
mutants from different tissues, exposure groups, and
doses simultaneously. Despite the apparently low recovery
of mutants by NGS due to the reduced sensitivity of
calling mutations from pooled DNA, the rapid
characterization of large numbers of mutants provides a
more accurate measure of mutation spectra and clonal
expansion. Although the method is applied to sequencing
lacZ mutants, this approach can be modified to identify
mutations in any reporter gene used in genetic toxicity
testing. With the higher throughput and reduced cost of-
fered by NGS, mutations induced by drugs or chemicals
can now be more routinely assessed. Understanding the
mode of action of different mutagenic agents enables
improved regulation of genotoxins and ultimately a reduc-
tion in harmful diseases such as cancer.
Availability of supporting data
Supporting data are available on the NCBI Sequence
Read Archive under the BioProject accession number
PRJNA284951.
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